Breast Cancer Breakthroughs Episode 5: Moving the Needle for HER2-positive Breast Cancer

An explosion of new targeted therapies has dramatically improved outcomes for an aggressive type of breast cancer called HER2-positive, yet only half of those living with metastatic HER2-positive breast cancer will live longer than 5 years. In this episode of Breast Cancer Breakthroughs, we’ll uncover how new research is moving the needle for HER2-positive breast cancer. We’ll hear from Dr. Ian Krop, an expert in HER2-positive breast cancer about the biggest issues researchers are trying to solve. We’ll also hear from Dr. Ciara O’Sullivan about an exciting clinical trial testing a new first-line therapy option for HER2-positive breast cancer that could replace the standard of care in place for over a decade.
Dr. Ian Krop is a medical oncologist at the Yale Cancer Center
Dr. Ciara O’Sullivan is a medical oncologist at the Mayo Clinic
Kelsey Hampton, PhD, is Senior Manager, Mission Communications at Susan G. Komen
Sign up for reminders about future episodes of Breast Cancer Breakthroughs here: www.komen.org/about-komen/our...
Link to Survey: susangkomen.iad1.qualtrics.co...
Clinical Trial Finder: www.breastcancertrials.org/BC...
Videos:
Breast Cancer Breakthroughs: Demystifying Treatment De-escalation: • Breast Cancer Breakthr...
Breast Cancer Breakthroughs: Unmet Needs in TNBC: • Breast Cancer Breakthr...
Under the Microscope: TROP2: A Promising Breast Cancer Drug Target: • TROP2: A Promising Bre...
Under the Microscope: HER2: A Driver of Breast Cancer: • HER2: A Driver of Brea...
Under the Microscope: HER2 Targeted Therapies: • HER2 Targeted Therapies
Resources:
HER2 Status: www.komen.org/breast-cancer/d...
HER2-targeted therapies:www.komen.org/breast-cancer/t...
HER2-targeted therapies for early breast cancer: www.komen.org/breast-cancer/t...
HER2-targeted therapies for metastatic breast cancer: www.komen.org/breast-cancer/m...
HER2DX Test: docwirenews.com/post/predicti...
Clinical Trials Mentioned in Episode:
TROPION-Breast01 Trial (Active, not recruiting): classic.clinicaltrials.gov/ct...
KATE3 Trial (Recruiting): classic.clinicaltrials.gov/ct...
HER2CLIMB-05 Trial (Recruiting): clinicaltrials.gov/study/NCT0...
DESTINY-Breast09 Trial (Recruiting): classic.clinicaltrials.gov/ct...
Time Stamps:
00:00 Introduction
01:06 New antibody-drug conjugate
01:59 New test to predict risk of relapse
02:43 What is HER2?
04:45 Biggest issues facing metastatic HER2+ breast cancer
07:33 Research strategies for HER2+ breast cancer
11:05 Featured Trial: HER2CLIMB-05